About Us

Modern therapies are often ineffective in treating life-changing diseases due to the complex and individual nature of the microbiome.

Age, ethnicity, diet and gender all have an impact on the composition of bacteria present in an individual’s gut, immune system or tumour physiology, which in turn influence whether drug treatments will have a positive or negative outcome.

Despite these factors, current drug development approaches remain uniform.

This leads to failed trials, poor outcomes and limited options for diverse populations, creating a significant financial impact on drug development, healthcare systems and a very personal cost for the people receiving treatment.

BioCorteX exists to change that.

At BioCorteX, we have the most extensive and varied knowledge graph of microbiome samples in existence, consisting of millions of samples. These include human, animal, soil and water microbiomes, carefully selected from over 165 geopolitical regions and representing diverse populations worldwide.

With the help of Carbon MirrorTM, our proprietary advanced simulation engine, we can test the mechanistic link between the varied microbiome and the different treatment responses, and use this information to develop positive changes in future treatments.

The actionable insights created from our advanced simulation engine means that BioCorteX can create new, sophisticated therapeutics that consider the differences in individuals and human populations. Therapeutics that are no longer uniform, but tailored to benefit different communities of people suffering from life-changing diseases. With a range of therapeutic options available, individuals will be able to confidently choose a treatment that works for them, successfully.

Positively changing the future of drug development, worldwide.

Meet the BioCorteX team

Amedra Basgaran - BioCorteX

Amedra
Basgaran

Senior Clinician
Scientist

Amanda Stafford - BioCorteX

Amanda
Stafford

Senior Data
Scientist

Eva Lymberopoulos - BioCorteX

Eva
Lymberopoulos

Microbiome
Data Scientist

David Delanoue - BioCorteX

David
Delanoue

Senior Data
Engineer

James Arney - BioCorteX

James
Arney

Platform
Engineer

Dionisios Korovilas - BioCorteX

Dionisios
Korovilas

Data
Engineer

Mohammad Tanweer - BioCorteX

Mohammad
Tanweer

Senior Cloud
Architect

Michael Hobbs - BioCorteX

Michael
Hobbs

Full Stack
Engineer

James Lam - BioCorteX

James
Lam

Clinician
Scientist

Muhannad Alomari - BioCorteX

Mo
Alomari

CTO &
Co-Founder

Lorna Watson - BioCorteX

Lorna
Watson

Executive
Assistant

Stephen Moore - BioCorteX

Stephen
Moore

Director of
Technology

Nik Sharma - Bio Cortex

Nik
Sharma

CEO &
Co-Founder

Meet the Board

Muhannad Alomari - BioCorteX

Muhannad
Alomari

CTO &
Co-Founder

Et modi cum iur, vellore rnatem ut occabor a est ipsae quissum core lit autes ipsum nos doloriae volore omni bea cullori berumque iliqui tet et officimet lam que venimint ene eius si ilicil inveritaspis simagni ssitaque voluptas sapicti aut liquo mo ipsum volo qui andanis delluptas il in rem est renimi, num ipiduscius electo etur, cus invene qui cuptatium as aut audipsamus di ditae ea volenih illuptaquam, sequae ratem nonem inum eaquis nossimillest ommolor erumquatur alic to dolupta voluptis quaecta tquatatem conse dolo que simus sitas aut aliqui autempos et asperum rehen. iduscius electo etur, cus invene qui cuptatium as aut audipsamus di

Nik Sharma - Bio Cortex

Nik
Sharma

CEO &
Co-Founder

Et modi cum iur, vellore rnatem ut occabor a est ipsae quissum core lit autes ipsum nos doloriae volore omni bea cullori berumque iliqui tet et officimet lam que venimint ene eius si ilicil inveritaspis simagni ssitaque voluptas sapicti aut liquo mo ipsum volo qui andanis delluptas il in rem est renimi, num ipiduscius electo etur, cus invene qui cuptatium as aut audipsamus di ditae ea volenih illuptaquam, sequae ratem nonem inum eaquis nossimillest o mmolor erumquatur alic to dolupta voluptis quaecta tquatatem conse dolo que simus sitas aut aliqui autempos et as mmolor erumquatur alic to dolupta voluptis quaecta tquatatem conse dolo que simus sitas aut aliqui autempos et as

Jackie
Hunter

Chair

Et modi cum iur, vellore rnatem ut occabor a est ipsae quissum core lit autes ipsum nos doloriae volore omni bea cullori berumque iliqui tet et officimet lam que venimint ene eius si ilicil inveritaspis simagni ssitaque voluptas sapicti aut liquo mo ipsum volo qui andanis delluptas il in rem est renimi, num ipiduscius electo etur, cus invene qui cuptatium as aut audipsamus di ditae ea volenih illuptaquam, sequae ratem nonem inum eaquis nossimillest ommolor erumquatur alic to dolupta voluptis quaecta tquatatem conse dolo que simus sitas aut aliqui autempos et asperum rehen.

Edward
Kliphuis

Board member & Partner
at Sofinnova Partners

Et modi cum iur, vellore rnatem ut occabor a est ipsae quissum core lit autes ipsum nos doloriae volore omni bea cullori berumque iliqui tet et officimet lam que venimint ene eius si ilicil inveritaspis simagni ssitaque voluptas sapicti aut liquo mo ipsum volo qui andanis delluptas il in rem est renimi, num ipiduscius electo etur, cus invene qui cuptatium as aut audipsamus di ditae ea volenih illuptaquam, sequae ratem nonem inum eaquis nossimillest ommolor erumquatur alic to dolupta voluptis quaecta tquatatem conse dolo que simus sitas aut aliqui autempos et asperum rehen.

Hussein
Kanji

Board Member & Partner
at Hoxton Ventures

Et modi cum iur, vellore rnatem ut occabor a est ipsae quissum core lit autes ipsum nos doloriae volore omni bea cullori berumque iliqui tet et officimet lam que venimint ene eius si ilicil inveritaspis simagni ssitaque voluptas sapicti aut liquo mo ipsum volo qui andanis delluptas il in rem est renimi, num ipiduscius electo etur, cus invene qui cuptatium as aut audipsamus di ditae ea volenih illuptaquam, sequae ratem nonem inum eaquis nossimillest ommolor erumquatur alic to dolupta voluptis quaecta tquatatem conse dolo que simus sitas aut aliqui autempos et asperum rehen.

Working in partnership with